Cell death in head and neck cancer pathogenesis and treatment

RAUDENSKÁ, Martina, Jan BALVAN and Michal MASAŘÍK. Cell death in head and neck cancer pathogenesis and treatment. CELL DEATH & DISEASE. LONDON: NATURE PUBLISHING GROUP, 2021, vol. 12, No 2, p. 1-17. ISSN 2041-4889. Available from: https://dx.doi.org/10.1038/s41419-021-03474-5.

Basic information

• Original name: Cell death in head and neck cancer pathogenesis and treatment
• Authors: RAUDENSKÁ, Martina (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution).
• Edition: CELL DEATH & DISEASE, LONDON, NATURE PUBLISHING GROUP, 2021, 2041-4889.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 10601 Cell biology
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 9.685
• RIV identification code: RIV/00216224:14110/21:00119012
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1038/s41419-021-03474-5
• UT WoS: 000621062800002
• Keywords in English: Cell death; head and neck cancer; pathogenesis; treatment
• Tags: 14110515, 14110518, rivok
• Tags: International impact, Reviewed

Abstract

Many cancer therapies aim to trigger apoptosis in cancer cells. Nevertheless, the presence of oncogenic alterations in these cells and distorted composition of tumour microenvironment largely limit the clinical efficacy of this type of therapy. Luckily, scientific consensus describes about 10 different cell death subroutines with different regulatory pathways and cancer cells are probably not able to avoid all of cell death types at once. Therefore, a focused and individualised therapy is needed to address the specific advantages and disadvantages of individual tumours. Although much is known about apoptosis, therapeutic opportunities of other cell death pathways are often neglected. Molecular heterogeneity of head and neck squamous cell carcinomas (HNSCC) causing unpredictability of the clinical response represents a grave challenge for oncologists and seems to be a critical component of treatment response. The large proportion of this clinical heterogeneity probably lies in alterations of cell death pathways. How exactly cells die is very important because the predominant type of cell death can have multiple impacts on the therapeutic response as cell death itself acts as a second messenger. In this review, we discuss the different types of programmed cell death (PCD), their connection with HNSCC pathogenesis and possible therapeutic windows that result from specific sensitivity to some form of PCD in some clinically relevant subgroups of HNSCC.

Links

• GA18-03978S, research and development project: Name: Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku

Investor: Czech Science Foundation

• MUNI/A/1246/2020, interní kód MU: Name: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Acronym: KAVASYKAMO)

Investor: Masaryk University

• MUNI/A/1698/2020, interní kód MU: Name: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF)

Investor: Masaryk University

• NU20J-08-00018, research and development project: Name: Exosomální RNA produkovaná fibroblasty asociovanými s nádorem jako relevantní marker v prognóze nádorů hlavy a krku

Investor: Ministry of Health of the CR, Subprogram 2 - junior